AbCellera Biologics
ABCL
154 hedge funds and large institutions have $547M invested in AbCellera Biologics in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 14 closing their positions.
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
12% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 42
8% more funds holding
Funds holding: 142 → 154 (+12)
0.27% more ownership
Funds ownership: 41.02% → 41.3% (+0.27%)
20% less capital invested
Capital invested by funds: $680M → $547M (-$133M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
32% less call options, than puts
Call options by funds: $1.82M | Put options by funds: $2.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$23.6M |
| 2 |
Man Group
London,
United Kingdom
|
+$3.94M |
| 3 |
Two Sigma Advisers
New York
|
+$3.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.16M |
| 5 |
Two Sigma Investments
New York
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$9.24M |
| 2 |
Lazard Asset Management
New York
|
-$7.1M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$4.41M |
| 4 |
DFO
Duquesne Family Office
New York
|
-$3.77M |
| 5 |
Goldman Sachs
New York
|
-$2.01M |
ABCL Hedge Fund Activity: Q1 2024 in Review
154 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2024, worth a combined $547M — down 20% from $680M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ABCL positions and 14 closed out — a net gain of 13 holders — while 47 added to existing stakes and 42 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $23.6M. The largest seller was Fidelity International, cutting an estimated $9.24M.
- 154 institutional investors held AbCellera Biologics (ABCL) as of Q1 2024, up from 142 in Q4 2023.
- Funds reported $547M of AbCellera Biologics stock for Q1 2024, down 20% quarter-over-quarter.
- 27 funds opened new AbCellera Biologics positions in Q1 2024 and 14 closed out, a net change of +13 holders.
- The largest AbCellera Biologics buyer in Q1 2024 was Baker Bros. Advisors, an estimated $23.6M added.
- The largest AbCellera Biologics seller in Q1 2024 was Fidelity International, an estimated $9.24M sold.
Based on aggregated 13F filings for Q1 2024.